UC和其它肠道疾病肠道菌丛结构的ERIC-PCR指纹图谱分析

目的建立溃疡性结肠炎（UC）和其它肠道疾病的肠道细菌DNA指纹图谱以分析其肠道菌丛的整体差异。方法采集19例UC、11例急性胃肠炎、6例IBS患者及11例正常对照者的粪便标本,提取肠道细菌总DNA;应用ERIC-PCR技术建立各组肠道细菌DNA指纹图谱,分析UC、急性胃肠炎、IBS患者及正常对照者的肠道菌丛的整体差异。结果经分析发现四组研究对象的肠道菌丛存在整体差异：UC组ERIC-PCR指纹图谱电泳DNA条带较少,IBS组、急性胃肠炎组和正常对照组ERIC-PCR指纹图谱电泳DNA条带多;UC组中有18个样本主带分布非常一致,均出现在约0.7 kb处,急性胃肠炎组主带分布也非常一致,均出现在约1.1 kb和0.8 kb处;正常对照组和IBS组主带位置无统一趋势。结论与IBS、急性胃肠炎和正常对照组相比较,UC组肠道优势菌群种类少;UC组和急性胃肠炎组各有分布较一致的主带;UC可能存在较单一的肠道优势细菌,推测其发病机制可能与特定的肠道优势细菌感染有关。     

炎症性肠病患者肠道菌丛结构特征的指纹图谱分析

目的建立炎症性肠病（IBD）患者和健康人肠道细菌DNA指纹图谱以分析其肠道菌丛的整体差异。方法应用肠杆菌基因间的重复共有序列（ERIC）-PCR技术建立10例IBD患者及10例正常对照者的肠道细菌DNA指纹图谱,分析IBD患者及正常对照者的肠道菌丛的整体差异。结果IBD患者及正常对照者的肠道菌丛存在整体差异,正常对照组ERIC．PCR指纹图谱电泳DNA条带多,主带位置无统一趋势;IBD组ERIC-PCR指纹图谱电泳DNA条带较少,且所有样本主带分布非常一致,均出现在约1．1kb处。结论正常人肠道细菌种类多,IBD患者少。IBD组1．1kb处主带可能为某一种肠道细菌中特有的序列,或为不同序列或几个序列的混合物。     

维吾尔医学4种正常体液质人群肠道菌群结构ERIC-PCR指纹图谱分析

目的了解维吾尔医学4种正常体液质人群肠道菌群结构的多样性以及4种体液质人群之间菌群分布的差异性。方法对141例健康人进行维吾尔医学分型,采集受检者粪便样品,提取总DNA,以此作模板获得反映肠道菌群组成的ERIC-PCR指纹图谱;计算各样本多样性指数和群落相似性系数。结果不同体液质人群肠道菌群结构多样性具有一定程度上的差异。血液质型人群肠道菌群结构具有较高的多样性和相似性,而粘液质人群肠道菌群结构的多样性程度较低。结论维医4种正常体液质人群肠道菌群分布结构存在一定程度的差异。     

溃疡性结肠炎患者肠道菌群变化的临床意义

目的观察溃疡性结肠炎(ulcerative colitis,UC)患者肠道大肠杆菌、双歧杆菌和乳酸杆菌的变化,探讨其与免疫异常的关系。方法收集博罗县人民医院2012年3月-2015年7月诊治的UC患者46例,缓解期20例、活动期26例。另取同期接受肠镜检查未见肠道病变的健康体检者28名作为对照。大肠杆菌、双歧杆菌和乳酸杆菌粪便标本培养计算含菌量,Th17和Treg细胞使用流式细胞仪检测。结果 UC组大肠杆菌数量显著高于对照组(P0.05),UC组双歧杆菌和乳酸杆菌数量显著低于对照组(P0.05)。UC缓解期患者大肠杆菌数量显著低于活动期患者(P0.05),UC缓解期患者双歧杆菌和乳酸杆菌数量显著高于活动期患者(P0.05)。UC组Th17细胞显著高于对照组(P0.05),UC组Treg细胞显著低于对照组(P0.05)。UC缓解期患者Th17细胞显著低于活动期患者(P0.05),UC缓解期患者Treg细胞显著高于活动期患者(P0.05)。UC患者大肠杆菌数量与Th17细胞呈正相关(r=0.312,P0.05),而与Treg细胞呈负相关(r=-0.241,P0.05)。双歧杆菌数量与Th17细胞呈负相关(r=-0.267,P0.05),而与Treg细胞呈正相关(r=0.236,P0.05)。乳酸杆菌数量与Th17细胞呈负相关(r=-0.226,P0.05),而与Treg细胞呈正相关(r=0.215,P0.05)。结论 UC患者大肠杆菌数量增加,而双歧杆菌和乳酸杆菌数量减少,这种菌群紊乱破坏了机体Th17/Treg细胞的免疫平衡,参与了UC病变的发生、发展过程。     

细菌16SrDNA荧光定量PCR法分析溃疡性结肠炎患者肠道菌群变化

目的 应用实时荧光定量PCR技术对溃疡性结肠炎(ulcerative colitis,UC)患者的粪便菌群进行定量分析.方法 研究对象包括30名UC活动期、30名UC缓解期患者及22名正常对照,收集其粪便标本.根据细菌的16S rDNA序列设计双歧杆菌属、乳酸杆菌属、肠球菌属和大肠杆菌的特异性引物.待测粪便标本提取细菌基因组DNA,进行实时荧光定量PCR反应测定16S rDNA拷贝数,分析不同细菌的数量.结果 UC活动期患者与正常对照相比,粪便中双歧杆菌(8.45±0.92 vs 9.10±0.78)、乳酸杆菌(8.11±0.94 vs 8.69±0.55)数量明显减少(P＜0.05),大肠杆菌(9.88±1.34 vs 9.71±0.92)和肠球菌(7.74±0.63 vs 7.61±0.49)无明显变化(P＞0.05);而UC缓解期患者粪便中4种细菌数量(双歧杆菌9.15±0.81,乳酸杆菌8.51±0.80,大肠杆菌9.54±1.64,肠球菌7.90±0.46)均与正常对照无明显差异(P＞0.05).结论 UC活动期患者粪便双歧杆菌、乳酸杆菌数量较正常对照明显减少,而UC缓解期患者粪便菌群与正常对照无明显差异.提示肠道菌群失调可能是具有UC遗传易感性个体发病的触发因素.     

腹泻型肠易激综合征与溃疡性结肠炎患者肠道菌群的关联分析

目的 通过比较腹泻型肠易激综合征(IBS-D)与溃疡性结肠炎(UC)患者的肠道菌群特征,探索两者的关联。方法 选择2020年5月至2021年12月在广州市第一人民医院消化内科住院的IBS-D和UC患者各24例,以及6名健康志愿者,收集新鲜人类粪便标本,提取DNA并进行16S rDNA高通量测序,对患者肠道菌群的多样性、优势菌群等进行统计学比较分析。结果 代表菌群丰富度和均匀度的α多样性分析中,IBS-D组和UC组的Sobs指数、Chao1指数、ACE指数、goods＿coverage指数、Shannon指数和Simpson指数分别为570.79±81.78 vs. 566.50±84.30(P=0.859)、765.35±101.32 vs. 749.15±90.53(P=0.562)、795.29±103.76 vs. 781.81±94.02(P=0.639)、1.00±0.00 vs. 1.00±0.00(P=0.261)、4.12±0.54 vs. 4.07±0.50(P=0.730)、0.85±0.08 vs. 0.85±0.07(P=0.904)。在Anosim检验(R=0...     

溃疡性结肠炎患者肠道菌群与病理变化关系的探讨

目的 探讨溃疡性结肠炎与肠道菌群的关系,观察肠黏膜病理改变状况.方法 对27例活动期溃疡性结肠炎患者及27例缓解期溃疡性结肠炎患者进行菌群分析,并与10例正常组进行比较;取全部溃疡性结肠炎患者肠黏膜制做病理切片.结果 活动期溃疡性结肠炎患者肠道舣歧杆菌、乳杆菌比正常组显著减少(P＜0.01),而大肠杆菌比正常组显著增加(P＜0.01),其他细菌差异无显著性(P＞0.05);缓解期溃疡性结肠炎患者各种细菌数量与正常对照组相比无显著性差异(P＞0.05);活动期与缓解期溃疡性结肠炎患者肠黏膜病理学改变明显不同.结论 活动期与缓解期溃疡性结肠炎患者存在肠道菌群失调,这种变化与其病理学改变有关联.     

肠道清洁对T-RFLP分析溃疡性结肠炎肠黏膜菌群多样性的影响

背景:肠道菌群失调在溃疡性结肠炎(UC)发病机制中的作用备受关注,末端限制性片段长度多态性(TRFLP)分析已广泛用于UC肠黏膜菌群多样性的研究,但采集肠黏膜标本前清洁肠道对T-RFLP分析黏膜菌群多样性的影响尚未明确。目的:探讨肠道清洁对T-RFLP分析UC患者肠黏膜菌群多样性的影响。方法:纳入UC患者38例,根据结肠镜检查前是否行肠道清洁将患者分为洗肠组和未洗肠组,分别于结肠镜下取直肠、乙状结肠交界处黏膜组织,以T-RFLP分析肠黏膜细菌多样性。结果:聚类分析显示,洗肠组、未洗肠组菌落构成成分相似。洗肠组与未洗肠组的丰度、Simpson指数、均匀度指数相比差异无统计学意义(P0.05),未洗肠组Shannon-Wiener指数较洗肠组显著增高(P0.05)。MspⅠ酶切结果显示,281 bp为未洗肠组特有优势末端限制片段(T-RF),37 bp为洗肠组特有优势T-RF。两组共有优势T-RF的曲线下面积(AUC)比较显示,洗肠组490 bp T-RF较未洗肠组显著增高(P0.05),其余优势T-RF的AUC差异无统计学意义(P0.05)。结论:肠道清洁对T-RFLP分析UC肠黏膜菌群多样性总体无明显影响,但可能会造成部分罕见菌群减少。     

溃疡性结肠炎患者结肠黏膜中Smad3和Smad7表达的研究

目的 探讨Smad3和Smad7在溃疡性结肠炎(UC)中的表达及其与临床病理因素的关系.方法 应用免疫组化SABC法检测60例UC患者的结肠黏膜及16例正常结肠黏膜(对照组)中Smad3和Smad7的表达.回顾性分析Smad3和Smad7的表达与UC临床分期、病变范围和病理组织学分级的关系.结果 Smad3在活动期和缓解期UC中的表达显著低于对照组(P值均＜0.05);其与病变范围无相关性(r_s=-0.192,P=0.141),但与病理组织学分级呈负相关(r_s=-0.283.P=0.029).Smad7在活动期和缓解期UC中的表达显著增强(P值均＜0.05),且活动期显著高于缓解期(Z=2.097,P=0.036);其与病变范围无关(r_s=0.066,P=0.614),但与病理组织学分级呈正相关(r_s=0.453.P=0.000).相关分析结果提示,Smad3和Smad7在UC中的表达水平间呈负相关(r_s=0.420,P=0.001).结论 转化生长因子-β1/Smad蛋白的异常表达与UC的发病机制密切相关,Smad7有可能成为反映UC疾病活动度的生物学指标.     

酒精性肝病演变过程中肠道菌群结构的变化及其临床意义

目的采用PCR、变性梯度凝胶电泳(DGGE)等方法分析酒精性脂肪肝(alcoholic fatty liver disease,AFLD)、酒精性肝炎(alcoholic hepatitis,AH)、酒精性肝硬化(alcoholic cirrhosis,AC)患者和健康对照组粪便菌群结构的差异性,以探索肠道菌群在酒精性肝病(alcoholic liver disease,ALD)发生和疾病进展中的作用。方法提取AFLD、AH、AC患者和健康对照组粪便DNA,以细菌通用引物PCR扩增粪便DNA样品中全部细菌16S rDNA高变区序列。将扩增产物通过DGGE分离,获得4组人群肠道细菌种属结构图谱,通过聚类图分析细菌种属结构的差异性,提取有差异的条带DNA进行克隆测序,并与GenBank序列比对鉴定差异性菌群。结果 (1)AC、AH患者的肠道菌群多样性明显少于AFLD患者和健康对照组(P0.05),而AFLD患者与健康对照组的肠道菌群多样性差异无统计学意义;(2)AC与其他3组菌群结构差异有统计学意义,AH与AFLD、健康对照组的肠道菌群结构之间存在一定的相似性,而后两者之间的肠道菌群结构无明显区别。(3)ALD患者出现肠道厚壁菌门的减少;当病情严重至AC时,患者肠道革兰阴性专性厌氧非发酵小杆菌及草绿色链球菌数量增多。结论随着ALD发展,肠道菌群多样性逐渐降低,菌群的相似性发生了改变;当病情严重至AC时,患者肠道革兰阴性专性厌氧非发酵小杆菌及草绿色链球菌数量增多。     

Increased incidence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis.

Faecal samples were collected from 23 patients with active ulcerative colitis, 15 patients with established ulcerative colitis in remission, 20 patients with active colitis of cause other than ulcerative colitis, and 20 normal control subjects. Ten coliform colonies were randomly selected from the faecal sample cultures and serotyped before the testing of each different serotype from each sample for adhesive or invasive properties on HeLa cell monolayers. In the patients with both active ulcerative colitis and ulcerative colitis in remission and those with other types of colitis one serotype tended to dominate the faecal coliform flora. In normal controls more variety was encountered. Thirty-five per cent of the patients with active ulcerative colitis and 27% of the patients with ulcerative colitis in remission had at least one adhesive or invasive faecal coliform as compared with 5% of the patients with other types of colitis and 5% of the normal controls. These findings are significant (P < 0.05) and may have aetiological and therapeutic significance.     

不同剂量双歧杆菌四联活菌片对轻、中度活动期溃疡性结肠炎患者肠道菌群失调的影响

目的研究不同剂量双歧杆菌四联活菌片对轻、中度活动期溃疡性结肠炎患者肠道菌群失调的影响。 方法采用前瞻性、随机、开放、对照研究的试验方法，选择2018年6月至2022年2月山东中医药大学第二附属医院消化中心就诊，明确诊断为伴有Ⅱ度肠道菌群失调的溃疡性结肠炎患者，随机分为A、B两组，A组应用常规剂量双歧杆菌四联活菌片联合美沙拉嗪治疗，B组应用双倍剂量双歧杆菌四联活菌片联合美沙拉嗪疗，主要观察终点为治疗4周后2组肠道菌群失调变化，次要观察终点为治疗4周后2组腹泻症状缓解情况、临床总疗效、内镜下黏膜愈合率及不良反应。 结果66例患者纳入研究，直肠炎22例，左半结肠炎有44例，轻度27例，中度39例，两组患者基线期临床特征基本相似。主要观察终点肠道菌群失调改善情况：B组(正常菌群25例，Ⅰ度菌群失调6例，Ⅱ度菌群失调2例)显著优于A组(正常菌群16例，Ⅰ度菌群失调12例，Ⅱ度菌群失调5例，P<0.05)。次要观察终点：腹泻症状缓解情况，与A组比较，B组患者腹泻症状恢复正常时间[(7.5±4.9)d比(11.8±4.8)d]及黏液脓血便消失时间[(8.8±5.8)d比(13.3±4.7)d]明显缩短(P<0.05)。临床总疗效：B组(临床缓解25例，临床应答6例，无效2例)显著优于A组(临床缓解16例，临床应答12例，无效5例，P<0.05)。内镜下黏膜愈合率：A组48.6%，B组76.7%(P<0.05)。不良反应：A组上腹部不适、大便次数增多1例，B组胃灼热、肠鸣音亢进1例，未见其他不良反应。两组肝肾功能正常。 结论双倍剂量的双歧杆菌四联活菌片治疗4周对轻、中度活动期溃疡性结肠炎肠道菌群失调的改善情况优于常规剂量双歧杆菌四联活菌片。     

Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.

In contrast with normal subjects where IgA is the main immunoglobulin in the intestine, patients with active inflammatory bowel disease (IBD) produce high concentrations of IgG from intestinal lymphocytes, but the antigens at which these antibodies are directed are unknown. To investigate the specificities of these antibodies mucosal immunoglobulins were isolated from washings taken at endoscopy from 21 control patients with irritable bowel syndrome, 10 control patients with intestinal inflammation due to infection or ischaemia, and 51 patients with IBD: 24 Crohn's disease (CD, 15 active, nine quiescent), 27 ulcerative colitis (UC, 20 active, seven inactive). Total mucosal IgG was much higher (p < 0.001) in active UC (median 512 micrograms/ml) and active CD (256 micrograms/ml) than in irritable bowel syndrome controls (1.43 micrograms/ml), but not significantly different from controls with non-IBD intestinal inflammation (224 micrograms/ml). Mucosal IgG bound to proteins of a range of non-pathogenic commensal faecal bacteria in active CD; this was higher than in UC (p < 0.01); and both were significantly greater than controls with non-IBD intestinal inflammation (CD p < 0.001, UC p < 0.01) or IBS (p < 0.001 CD and UC). This mucosal IgG binding was shown on western blots and by enzyme linked immunosorbent assay (ELISA) to be principally directed against the bacterial cytoplasmic rather than the membrane proteins. Total mucosal IgA concentrations did not differ between IBD and controls, but the IgA titres against faecal bacteria were lower in UC than controls (p < 0.01). These experiments show that there is an exaggerated mucosal immune response particularly in active CD but also in UC directed against cytoplasmic proteins of bacteria within the intestinal lumen; this implies that in relapse of IBD there is a breakdown of tolerance to the normal commensal flora of the gut.     

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis

BACKGROUND: The intestinal microbiota plays a critical role in the pathophysiology of pouchitis, a major complication after ileal pouch anal anastomosis in patients with ulcerative colitis. Recently, controlled trials have demonstrated that probiotics are effective in maintenance of remission in pouchitis patients. However, the mechanism by which therapy with probiotics works remains elusive. This study explores the role of the bacterial and fungal flora in a controlled trial for maintenance of remission in pouchitis patients with the probiotic VSL#3 compound. METHODS: The mucosa associated pouch microbiota was investigated before and after therapy with VSL#3 by analysis of endoscopic biopsies using ribosomal DNA/RNA based community fingerprint analysis, clone libraries, real time polymerase chain reaction (PCR), and fluorescence in situ hybridisation. Patients were recruited from a placebo controlled remission maintenance trial with VSL#3. RESULTS: Patients who developed pouchitis while treated with placebo had low bacterial and high fungal diversity. Bacterial diversity was increased and fungal diversity was reduced in patients in remission maintained with VSL#3 (p = 0.001). Real time PCR experiments demonstrated that VSL#3 increased the total number of bacterial cells (p = 0.002) and modified the spectrum of bacteria towards anaerobic species. Taxa specific clone libraries for Lactobacilli and Bifidobacteria showed that the richness and spectrum of these bacteria were altered under probiotic therapy. CONCLUSIONS: Probiotic therapy with VSL#3 increases the total number of intestinal bacterial cells as well as the richness and diversity of the bacterial microbiota, especially the anaerobic flora. The diversity of the fungal flora is repressed. Restoration of the integrity of a "protective" intestinal mucosa related microbiota could therefore be a potential mechanism of probiotic bacteria in inflammatory barrier diseases of the lower gastrointestinal tract.     

溃疡性结肠炎患者血清低氧诱导因子-1α的检测及意义

[目的]检测溃疡性结肠炎患者血清低氧诱导因子-1α(HIF-1α)的含量,探讨其在溃疡性结肠炎发病机制中的调控作用及其与患者病情活动性和严重性的关系。[方法]采用酶联免疫吸附试验(ELISA)定量检测13例缓解期(缓解期组)、47例活动期(活动期组)UC患者及10例健康体检者(正常对照组)血清中HIF-1α含量,并对活动期组患者行肠镜检查,评价病情轻重程度。[结果]活动期组HIF-1α含量[(73.21±28.65)ng/L]显著高于缓解期组[(44.54±14.75)ng/L]与正常对照组[(42.83±15.49)ng/L],P0.05;缓解期组与正常对照组比较差异无统计学意义(P0.05)。HIF-1α与病情活动性、病情分型及内镜表现分级呈正相关。[结论]HIF-1α作为一种转录因子可能在UC发病机制中充当重要角色,并可能作为评价UC患者病情活动性及严重程度的良好指标。     

EEG in ulcerative colitis.

Electroencephalographic tracings of 50 patients with ulcerative colitis (UC) were compared with those of 75 controls. In the UC patients a 24% incidence of abnormal tracings was found as compared with an 8% incidence in the controls. A higher incidence of abnormal electroencephalograms was found among active cases of UC than among those in remission. The meaning of these results is not yet clear.     

炎症性肠病的抗生素治疗

炎症性肠病（IBD）主要包括克罗恩病（CD）和溃疡性结肠炎（UC）,近年越来越多的证据提示肠道细菌在其发病中发挥重要作用.虽然目前尚未发现特异性细菌与IBD的发病相关,但随着现代微生物学的发展以及肠道细菌与IBD研究的进展,发现肠道细菌可能是参与IBD始动和持续的因素.因此,采用抗生素治疗IBD可能是一种有效的治疗措施.本文就抗生素对活动期CD,CD肛周病变、CD术后复发以及活动期UC和囊袋炎的疗效作一综述.     

Relationship between clinical features and intestinal microbiota in Chinese patients with ulcerative colitis

BACKGROUNDDysbacteriosis may be a crucial environmental factor for ulcerative colitis (UC). Further study is required on microbiota alterations in the gastrointestinal tract of patients with UC for better clinical management and treatment.AIMTo analyze the relationship between different clinical features and the intestinal microbiota, including bacteria and fungi, in Chinese patients with UC. METHODSEligible inpatients were enrolled from January 1, 2018 to June 30, 2019, and stool and mucosa samples were collected. UC was diagnosed by endoscopy, pathology, Mayo Score, and Montreal classification. Gene amplicon sequencing of 16S rRNA gene and fungal internal transcribed spacer gene was used to detect the intestinal microbiota composition. Alpha diversity, principal component analysis, similarity analysis, and Metastats analysis were employed to evaluate differences among groups. RESULTSA total of 89 patients with UC and 33 non-inflammatory bowel disease (IBD) controls were enrolled. For bacterial analysis, 72 stool and 48 mucosa samples were obtained from patients with UC and 21 stool and 12 mucosa samples were obtained from the controls. For fungal analysis, stool samples were obtained from 43 patients with UC and 15 controls. A significant difference existed between the fecal and mucosal bacteria of patients with UC. The α-diversity of intestinal bacteria and the relative abundance of some families, such as Lachnospiraceae and Ruminococcaceae, decreased with the increasing severity of bowel inflammation, while Escherichia-Shigella showed the opposite trend. More intermicrobial correlations in UC in remission than in active patients were observed. The bacteria-fungi correlations became single and uneven in patients with UC.CONCLUSIONThe intestinal bacteria flora of patients with UC differs significantly in terms of various sample types and disease activities. The intermicrobial correlations change in patients with UC compared with non-IBD controls.     

炎症性肠病肠道黏膜细菌谱的研究

目的以16S-rDNA基因序列测定方法研究日本炎症性肠病（inflammatoryboweldisease,1BD）患者与正常对照肠镜标本中细菌构成谱。方法纳入2010年11月-2011年6月在日本名古屋大学附属病院接受肠镜检查患者14例,其中4例活动期溃疡性结肠炎（ulcerativecolitis,UC）患者（8个标本）,3例缓解期UC（5个标本）,2例活动期克罗恩病（Crohn’Sdisease,CD）（4个标本）,和正常对照5例（10个标本）,共收集肠镜27个标本。应用16S-rDNA基因序列测定方法检测肠道黏膜细菌谱。比较不同组间、不同部位标本的细菌构成差异。结果共取得796个细菌16S-rDNA基因序列。这些序列分属于5个门（phylum）：厚壁菌（Firmicutes）、拟杆菌（Bacteroidetes）、变形杆菌（Proteobacteria）、梭杆菌（Fusobacteria）和未分类细菌（unclassifiedBacteriao活动期UC组和活动期CD组中厚壁菌门细菌构成比低于缓解期UC组和正常对照组。CD组中细菌种类减少,CD组中变形杆菌门细菌高于UC组和对照组。结论本研究证实了IBD组肠道黏膜细菌构成谱不同于正常对照组,且有细菌种类减少趋势。     

凝结芽孢杆菌活菌TBC169株对右旋葡聚糖硫酸钠引发大鼠溃疡性结肠炎的治疗作用

目的:研究凝结芽胞杆茵(Bacillus coagulans,BC)对右旋葡聚糖硫酸钠(DSS)引发的大鼠溃疡性结肠炎(UC)的治疗作用.方法:采用DSS引发大鼠UC,分别用10~7和10~6 CFU/mL BC、0.02g/mL柳氮磺胺吡啶(SASP)和生理盐水(NS)处理.21d后测定动物体质量、结直肠湿重、肠黏膜溃疡、糜烂点数及面积、髓过氧化物酶活性和肠道菌群培养.结果:治疗21d后,各组中大鼠的体质量增加,以BC10~7 CFU/mL增重明显(P<0.05);各治疗组中大鼠的结直肠湿重、肠溃疡糜烂点数、面积、MPO活性与模型组比较均有显著性差异(P<0.05或P<0.01或P<0.001);肠道菌群分析,造型后双歧杆菌数明显下降(P<0.05),治疗后各组的双歧杆菌数量均明显增加(P<0.01或P<0.001),以BC组和SASP组增加最明显(P<0.01或P<0.001).BC在肠道定植.结论:BC对DSS引发的大鼠UC有明显治疗作用.